Brief: Aytu Biopharma - AR101 Granted Orphan Designation In Europe For Treatment Of Ehlers-Danlos Syndrome

Aytu Biopharma

02/03/2022 13:29

March 2 (Reuters) - Aytu Biopharma Inc  AYTU.O :
    * AYTU BIOPHARMA INC- AR101 GRANTED ORPHAN DESIGNATION IN
EUROPE
FOR THE TREATMENT OF EHLERS-DANLOS SYNDROME
    * AYTU BIOPHARMA INC- PLANS TO INITIATE ITS PREVENT TRIAL TO
ASSESS THE SAFETY AND EFFICACY OF AR101 IN PATIENTS WITH
COL3A1-CONFIRMED VEDS BY MID-2022


Further company coverage:  AYTU.O 

 ((Reuters.Briefs@thomsonreuters.com;))